Revance Therapeutics (RVNC) reported positive results Tuesday from a pair of late-stage clinical trials of its longer-lasting version of a Botox-like wrinkle reducer. The product, if approved, aims to take on market leader Allergan.

The Revance product, known as RT002, is an injectable form of botulinum toxin formulated to last for six months. The company has pitched RT002 as a “better” Botox, which is also injected but is generally durable for three to four months.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.